Fibrin sealant (tisseel) - Biologic Drug Details

Summary for fibrin sealant (tisseel)

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for fibrin sealant (tisseel)

Physiological Effect	Increased Coagulation Activity Increased Coagulation Factor Activity
Established Pharmacologic Class	Human Blood Coagulation Factor
Chemical Structure	Blood Coagulation Factors

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for fibrin sealant (tisseel) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for fibrin sealant (tisseel) Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for fibrin sealant (tisseel) Derived from Patent Text Search

No patents found based on company disclosures

Fibrin sealant (tisseel) Market Analysis and Financial Projection

Last updated: February 16, 2026

What Are the Market Dynamics for Tisseel?

Tisseel is a fibrin sealant used in surgical procedures to control bleeding, promote wound healing, and provide tissue adhesion. It is manufactured by CSL Behring and approved in many jurisdictions for various indications, including orthopedic, cardiac, neurological, and general surgery.

Market Size and Growth Rate

The global fibrin sealant market, driven primarily by Tisseel, was valued at approximately $850 million in 2022. It is projected to reach $1.4 billion by 2030, with a compound annual growth rate (CAGR) of 6.4% (Fortune Business Insights, 2023).

Key Market Drivers

• Increase in surgical procedures: The rising number of complex surgeries globally expands demand.
• Advancements in minimally invasive surgeries: Fibrin sealants are critical in minimally invasive procedures due to their ease of application.
• Growing acceptance in trauma and vascular surgeries: The need for effective hemostasis supports growth.
• New approved indications: Expanded regulatory approvals and off-label use increase market penetration.

Major Market Players

Company	Product Name	Market Share (Estimated)	Notes
CSL Behring	Tisseel	Approx. 50%	Market leader, extensive clinical data
Baxter International	Evicel	Estimated 20%	Focuses on hemostatic applications
Novoseven	Other brands	Estimated 10-15%	Smaller market presence
Others	Various	Remainder	Geographic and niche specialization

Regulatory and Reimbursement Landscape

• Multiple jurisdictions, including the US and EU, classify Tisseel as a medical device with CE marking and FDA approval.
• Reimbursement codes facilitate coverage, but high costs remain an obstacle in some regions.
• Recent efforts aim to expand usage in outpatient settings to reduce costs.

What Is the Financial Trajectory for Tisseel?

Revenue Trends

• CSL Behring's fibrin sealant revenues accounted for approximately $600 million in 2022.
• The product's revenue has grown at roughly 5-7% annually over the last five years, with notable boosts from new indications.

Cost Structure and Pricing

• The average price per unit varies geographically, typically ranging from $250 to $600.
• The cost to produce Tisseel involves the collection and processing of human plasma, purification, and quality controls, making it expensive.
• Price adjustments follow market dynamics, regulatory changes, and competition.

R&D and Investment

• CSL Behring invests significantly in pipeline development, including next-generation fibrin sealants with extended shelf life or enhanced tissue adhesion properties.
• Clinical trials focus on expanding indications to surgical and non-surgical uses, such as trauma.

Competitive Pricing and Market Entry

• New entrants and biosimilar products impact market prices.
• Pricing strategies reflect the product's value in reducing operative time and blood transfusions.

Future Revenue Potential

• The increasing adoption of Tisseel in emerging markets and outpatient surgeries presents substantial growth.
• Upgrading formulations or combining with biologics could allow premium pricing.
• The expected CAGR of approximately 6.4% sustains revenue growth toward the projected $1.4 billion by 2030.

What Are the Challenges and Risks?

• High costs restrict broader adoption in price-sensitive markets.
• Competition from newer agents and biosimilars could pressure prices.
• Regulatory hurdles for new indications or markets can delay revenue expansion.
• Supply chain issues related to plasma sourcing could impact production.

Summary of Key Market and Financial Data

Aspect	Data/Estimate	Source
2022 Market Size	$850 million	Fortune Business Insights (2023)
2030 Market Projection	$1.4 billion	Fortune Business Insights (2023)
Revenue (CSL Behring, 2022)	$600 million	CSL Behring financial reports
CAGR (2022-2030)	6.4%	Fortune Business Insights (2023)
Price Range per Unit	$250 - $600	Market surveys
Main Competitors	Evicel, other biosimilar fibrin sealants	Market reports

Key Takeaways

• The fibrin sealant market is expanding, primarily driven by surgical procedure volume and technological advancements.
• Tisseel maintains a dominant market share but faces increasing competition.
• Revenue growth remains steady with projections reaching $1.4 billion by 2030, supported by ongoing R&D and geographic expansion.
• Cost and reimbursement factors influence adoption; pricing strategies are evolving alongside market competition.
• Future growth hinges on regulatory approvals for new indications, biosimilar entry, and innovations in formulation.

FAQs

1. How does Tisseel compare to its competitors?
Tisseel has the largest market share due to extensive clinical data and regulatory approvals. Competitors like Evicel target specific markets with lower pricing but lack the broad indication spectrum.

2. What are the main applications of Tisseel?
Tisseel is used in vascular, neurological, orthopedic, and general surgeries primarily for hemostasis, tissue sealing, and wound healing.

3. How does regulation affect Tisseel's market?
Regulatory approvals in different countries influence access and usage. Delays or restrictions can slow revenue growth or limit geographic expansion.

4. What are the key factors influencing Tisseel's pricing?
Pricing depends on market demand, manufacturing costs, competition, and reimbursement policies. Cost-effectiveness in reducing operative time also impacts perceived value.

5. What future markets or indications could drive growth?
Emerging uses in regenerative medicine, minimally invasive procedures, and trauma care, along with expanded indications for surgical hemostasis, could boost revenues.

---

Citations:

1. Fortune Business Insights, "Fibrin Sealant Market Size, Share & Industry Analysis," 2023.
2. CSL Behring, Financial Reports, 2022.
3. Market research reports on hemostatic agents and surgical adhesives.